Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab in Pediatric and Adolescent Patients With Active Juvenile Idiopathic Arthritis
NCT07517575Phase 2Recruiting
- Sponsor
- R-Pharm
- Start
- Mar 2023
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of olokizumab in juvenile idiopathic arthritis (JIA), sponsored by R-Pharm. Started Mar 2023; status: recruiting.
02
Drugs
olokizumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT07517575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517575.